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Abstract
Peripheral nerve injuries are debilitating, and current clinical management is limited 
to surgical intervention, which often leads to poor functional outcomes. Development 
of pharmacological interventions aimed at enhancing regeneration may improve this. 
One potential pharmacological target is the P2X purinergic receptor 7 (P2X7R) ex-
pressed in Schwann cells, which is known to play a role during the development 
of the peripheral nerves. Herein, we analysed differences in regeneration between 
genetically engineered P2X7 knockout mice and wild-type controls, using in vivo 
and ex vivo models of peripheral nerve regeneration. We have found that the speed 
of axonal regeneration is unaltered in P2X7 knockout mice, nevertheless regenerated 
P2X7 knockout nerves are morphologically different to wild-type nerves following 
transection and immediate repair. Indeed, the detailed morphometric analysis at 4 
and 8 weeks after injury showed evidence of delayed remyelination in P2X7 knock-
out mice, compared to the wild-type controls. Furthermore, the Wallerian degenera-
tion phase was unaltered between the two experimental groups. We also analysed 
gene expression changes in the dorsal root ganglia neurones as a result of the pe-
ripheral nerve injury, and found changes in pathways related to pain, inflammation 
and cell death. We conclude that P2X7 receptors in Schwann cells may be a putative 
pharmacological target to control cell fate following injury, thus enhancing nerve 
re-myelination.
K E Y W O R D S
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1 |  INTRODUCTION
Peripheral nerve injuries, occurring as a result of trauma to 
upper and lower limbs, are common and debilitating. The 
most severely affected patients may face permanent dis-
ability, chronic pain, and psychological challenges. Current 
treatments, merely limited to surgical repair, are ineffective 
and lead to poor functional recovery (Zochodne,  2012). 
There are no pharmacological interventions that can im-
prove regeneration and repair; however, several molecules 
and receptors, targeting mainly Schwann cells, have been 
suggested as potential candidates for pharmaceutical ther-
apies (Magnaghi et  al.,  2009). These pharmacological 
strategies to enhance nerve regeneration include the use of 
neurosteroids, neurotransmitters and other small molecules 
(Martinez de Albornoz et  al.,  2011). Indeed, research has 
shown that receptors for neurotransmitters such as γ-ami-
nobutyric acid (GABA), Acetylcholine (Ach), and adenos-
ine triphosphate (ATP), are able to modulate physiological 
parameters in Schwann cells, which may be exploited to 
improve peripheral nerve regeneration outcomes (Faroni, 
Castelnovo, et al., 2014; Faroni, Smith, et al., 2014; Uggenti 
et al., 2014). Mice lacking receptors for GABA, Ach and ATP 
have shown an altered peripheral nerve development, that re-
sults in specific peripheral nervous system (PNS) phenotypes 
(Faroni, Smith, et al., 2014; Magnaghi et al., 2008; Uggenti 
et al., 2014).
The P2X purinergic receptor 7 (P2X7R) is a plasma 
membrane ligand-gated ion channel operated by ATP. In 
Schwann cells, these receptors bind ATP released from 
dorsal root ganglia (DRG) and axons in an activity-depen-
dent manner; however, the effects of ATP on downstream 
purinergic signalling pathways involved in peripheral 
nerve regeneration, myelination and function are largely 
unknown (Fields & Stevens, 2000; Stevens & Fields, 2000; 
Stevens et  al.,  1998). Previous work by our group has 
shown that P2X7R is expressed predominantly in myelin-
ating Schwann cells and that, during development, lack of 
P2X7R causes Schwann cells to commit to a non-myelin-
ating phenotype (Faroni, Smith, et al., 2014). These results 
were obtained by studying P2X7R knockout mice devel-
oped by GlaxoSmithKline (GSK) (Chessell et  al.,  2005); 
however, another mouse strain with ablation of P2X7R was 
developed by Pfizer Inc. (Solle et al., 2001), and the two 
models have been reported to possess similar, although 
not identical, phenotypes (Sim et al., 2004). In the current 
study, we aimed to confirm the PNS phenotype, we previ-
ously observed in the GSK mouse model, in Pfizer's mice 
strain. Moreover, we aimed to determine whether P2X7R 
affects the speed of degeneration, regeneration and myelin 
formation following nerve transection. This will be done 
through characterising the differences between genetically 
engineered P2X7R knock out (KO) mouse model, and 
wild-type (WT) controls, in ex vivo and in vivo models of 
peripheral nerve injury and repair.
2 |  MATERIALS AND METHODS
2.1 | Experimental mice and surgical 
procedures
All animal experiments were performed in accordance with 
the UK Animals (Scientific Procedures) Act, 1986. Pfizer 
P2X7 KO mice (B6.129P2-P2rx7tm1Gab/J) were acquired from 
The Jackson Laboratory, US (Solle et  al.,  2001). C57BL/6 
mice obtained from the Biological Service Facility of the 
University of Manchester were used as WT controls. All mice 
were 3–4 month old males. For surgical transection, animals 
were anaesthetised with isoflurane and the sciatic nerves 
were transected. Immediately following transection the sci-
atic nerves were repaired with 11-0 sutures under an operat-
ing microscope (Leica, UK). For the non-repair group, the 
proximal and distal stumps of sciatic nerve were sutured to an 
adjacent muscle. One week after the axotomy and no repair 
surgery, mice underwent terminal anaesthesia with carbon, 
dioxide (CO2) and cervical dislocation. The lumbar 4 and 5 
DRGs were removed via cutting of the central and peripheral 
branch, close to the ganglia. The DRGs were harvested from 
the injured (lnj) and the contralateral control side (Ctrl) in 
all mice (P2X7 KO and WT). Samples were collected with 
n = 5 for the four groups and stored at −40°C until real time 
PCR analyses. For the injury and repair experiments, tissues 
were collected at 1 and 2 weeks and processed for immuno-
histochemistry (n = 5). Furthermore, we performed long term 
studies at 4 and 8 weeks survival for morphometric analyses 
through transmission electron microscopy analyses (n = 4).
2.2 | Genotyping
Ear clippings from KO and WT animals were lysed 
for 2  hr at 55°C and DNA was isolated by adding 
phenol:chloroform:isoamyl alcohol solution (25:24:1; 
Sigma-Aldrich, UK). Lysis buffer was: 100  mM NaCl, 
10  mM Tris Buffer, 1  mM EDTA, 1% SDS, 0.1  mg/ml 
Proteinase K (all from Sigma-Aldrich). For polymerase 
chain reaction (PCR), each well contained 1 μl of extracted 
DNA and 9 μl master mix (5X Green GoTaq Flexi buffer, 
MgCl2 2  mM, dNTPs 0.2  mM, primers mix 0.5  μM each, 
GoTaq DNA polymerase 5  U/μl; Promega, Southampton, 
UK). Primers were obtained from Sigma and sequences were 
as follows: WT allele: 5′–TGG ACT TCT CCG ACC TGT 
CT–3′ and 5′–TGG CAT AGC ACC TGT AAG CA–3′; KO 
allele: 5′–CTT GGG TGG AGA GGC TAT TC–3′ and 5′–
AGG TGA GAT GAC AGG AGA TC–3′. The PCR protocol 
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used can be found on the Jackson Laboratories website, and 
it involved 28 cycles of 94°C for 15 s, annealing at 50°C for 
15 s, and extension at 72°C for 10 s; followed by 72°C of 
final extension for 2 min and hold at 4°C. Following PCR, 
samples were loaded onto a 1.5% agarose gel and were run at 
80V for 1.5 hr before analysis with an AlphaImager 2200 gel 
documentation system (Alpha Innotech/Proteinsimple, Santa 
Clara, CA, USA).
2.3 | Western blot
Sciatic nerves were first homogenised using a tissue ruptor 
(Qiagen, Manchester, UK) and left to lyse on ice in lysis buffer 
for 30 min. Samples were then freeze/thawed and centrifuged 
at 13,000 g, 4°C, for 15 min (IEC CL31R Multispeed; Fisher 
Scientific, Loughborough, UK) before separating the super-
natant from the pellet. Supernatant protein concentration was 
determined using the Bio-Rad detergent-compatible protein 
assay (Bio-Rad Laboratories, Hemel Hempstead, UK) and 
standard curve of bovine serum albumin (BSA; Sigma-
Aldrich) standards, and a spectrophotometer (Asys UVM340 
Microplate Reader; Bichrom, Cambridge, UK). Ten micro-
grams of protein from each sample were mixed with load-
ing buffer (2X buffer: Tris-HCl 100 mM, pH 6.8, SDS 4% 
(w/v), bromophenol blue 0.2% (w/v), glycerol 20% (v/v), 
β-mercaptoethanol 200  mM; Sigma-Aldrich), and boiled 
at 100°C for 3 min, followed by centrifugation at 13,000 g 
at room temperature for 1  min. Samples were loaded onto 
a 10% polyacrylamide gel (40% acrylamide 29:1; Sigma-
Aldrich) with protein marker (ColorPlus prestained protein 
marker, 8–175  kDa; New England Biolabs, Hitchen, UK) 
and ran for 90–120 min at 80–120 V. Gels were transferred 
onto a nitrocellulose membrane (Amersham Hybond-ECL; 
GE Healthcare, Little Chalfont, UK) with a Bio-Rad wet 
transfer apparatus (transfer buffer: Tris-base 25 mM, glycine 
192 mM, methanol 20% (v/v) at 80 V for 1 hr. To confirm 
protein transfer membranes were then treated with ponceau 
red (ponceau 0.1% (w/v), acetic acid 0.5% (v/v)). Membranes 
were blocked in 5% (w/v) skimmed milk in tris-buffered 
saline-Tween (TBST; Tween-20 0.5% (v/w), NaCl 140 mM, 
Tris 10 mM, pH 7.5) for 30–60 min and incubated in primary 
antibodies overnight at 4°C on a shaker. The following day 
membranes were washed for 30 min in TBST, incubated in 
horseradish peroxidase (HRP)-conjugated secondary anti-
bodies at room temperature for 1 hr, and washed for 30 min 
in TBST. Primary antibodies were used at the following 
dilutions: anti-protein zero (P0), 1:200 (Abcam, UK); anti-
myelin basic protein (MBP), 1:200 (Millipore, UK); anti- 
myelin associated glycoprotein (MAG), 1:200 (Cell Signalling 
Technologies, UK). Rabbit secondary -HRP antibodies were 
used 1:500 (Cell Signalling Technologies, UK). Membranes 
were treated with pico- or femtochemiluminescence mixes 
(SuperSignal West pico/femto chemiluminescent substrate; 
Fisher Scientific) for 5 min for signal detection. Luminescent 
bands were imaged using a Kodak Image Station 4000mm 
PRO. Densitometry analysis was performed in Image J 
(version 1.47f, NIH, USA). Bands were normalised to the 
housekeeping protein β-tubulin data was expressed as the 
percentage versus the WT control.
2.4 | Immunohistochemistry
Following overnight fixation in 4% (w/v) paraformaldehyde 
(PFA) at 4°C, sciatic nerves were cryoprotected in 15% (w/v) 
sucrose in phosphate buffered saline (PBS) which was re-
placed daily for 3 days. Nerves were embedded in optimal 
cutting temperature embedding matrix (Raymond A Lamb, 
Eastbourne, UK), and stored at −80°C until further process-
ing. Nerves were then sliced into 15 μm longitudinal sections 
using a cryostat (OTF; Bright Instruments, Cambridgeshire, 
UK) set at −20°C. Slices were dried overnight at 37°C, be-
fore permeabilisation in 0.2% (v/v) Triton X-100 in PBS for 
1 hr at room temperature, and a further two washes in PBS 
for 5 min. Sections were then blocked in 5% blocking serum 
(Normal Goat Serum, Sigma) diluted 1:100 in antibody dilu-
ent (0.03% (v/v) Triton, 0.10% (w/v) BSA, 0.10% (w/v) so-
dium azide) for 1 hr at room temperature. Sections were then 
incubated in a rabbit primary antibody labelling neurofila-
ment 200 (NF200, Sigma-Aldrich) overnight at 4°C. After 
incubation, sections were washed in PBS for 5  min twice, 
incubated in Alexa-488 labelled anti-rabbit secondary an-
tibody raised in goat (Thermo Scientific, UK) for 2  hr at 
room temperature and in dark conditions, and then washed 
twice in PBS for 5 min. Finally, coverslips were fitted to the 
slides using Vectashield with 4′,6-diamidino-2-phenylindole 
(DAPI) H-1200 (Vector Laboratories, Peterborough, UK). 
Fluorescence microscopy analysis was performed with an 
Olympus BX60 fluroscence microscope, and images were re-
corded in Image ProPlus v 6.0 (Media Cybernetics, Rockville, 
MD, USA). Tiled images were merged using Photoshop CS6 
(Adobe).
2.5 | Explant culture as Wallerian 
Degeneration (WD) Model
Following terminal anesthesia using carbon dioxide (CO2) 
and cervical dislocation, approximately a 10  mm segment 
of the sciatic nerves (from both legs) were removed from 
both P2X7 KO and WT mice (n = 3). Three nerve segments 
from each group nerve were frozen immediately in liquid 
nitrogen to ensure Wallerian degeneration could not occur. 
These samples are referred to as time zero (T0). Contralateral 
KO and WT sciatic nerves were divided into 1–2 mm long 
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sections and cultured as floating nerve explants in Dulbecco's 
modified eagles medium (Sigma), containing 10% (v/v) fetal 
bovine serum (Labtech), 2% (v/v) L-glutamine (sigma) and 
1% (v/v) penicillin-streptomycin (Sigma). The cultures were 
maintained at 37°C in a humidified atmosphere containing 
5% Carbon dioxide (CO2) for 72 hr to recapitulate Wallerian 
degeneration ex vivo. After culture, samples were then fro-
zen using liquid nitrogen and stored in a −40°C freezer until 
real time PCR analyses. These samples are referred to as T72 
(time point 72 hr).
2.6 | Real-time quantitative polymerase 
chain reaction
The RNeasy lipid tissue mini kit (Qiagen) was used for 
the extraction of RNA from the sciatic nerves and DRG 
samples. Tissues were homogenised using the Qiagen 
Tissue Ruptor (for nerves) or mortar and pestle (DRG). 
Chloroform was then added and the tissue was centrifuged 
at 120,000 g for 15 min to separate the nucleic acids in the 
aqueous phase. Following ethanol addition, the mixture was 
applied to RNeasy spin column to purify RNA and get rid 
of contaminants. The concentration of RNA obtained from 
both tissues types was then determined by the measuring 
the absorbance at 260 nm using a Nanodrop-1000 spectro-
photometer (Thermo Scientific). The extracted RNA was 
reverse transcribed using the RT2 First Strand Kit (Qiagen) 
and a PTC-200 Peltier Thermal Cycler (MJ Research) ac-
cording to the manufacturer's instructions. Either 100  ng 
(DRG) or 140 ng (nerves) of RNA were reverse transcribed. 
Primers for RT-PCR are listed in Table  1. PCR reactions 
were performed with a Corbett Research thermocycler, 
using ad RT2 SYBR Green kit (Qiagen), and data were 
Gene Primer sequence (5′–3′)
PL 
(bp) Reference
CASP2 FW: CCACAGATGCTACGGAACA 99 Hanoux 
et al. (2007)RV: GCTGGTAGTGTGCCTGGTAA
CASP3 FW: TGCAGCATGCTGAAGCTGTA 150 Gesing et al. (2015)
RV: GAGCATGGACACAATACACG
ATF3 FW: GCTGCCAAGTGTCGAAACAAG 331 Allen-Jennings 
et al. (2001)RV: CAGTTTTCCAATGGCTTCAGG
GAP43 FW: TGTGGGAGTCCACTTTCCTC 64 Namsolleck 
et al. (2013)RV: GAACGGAACATTGCACACAC
NGF-B FW: CCAGTGAAATTAGGCTCCCTG 143 Namsolleck 
et al. (2013)RV: CCCTTGGCAAAACCTTTATTGGG
GAL FW: TGGAGGAAAGGAGACCAGGAAG 100 He et al. (2005)
RV: GCCTCTTTAAGGTGCAAGAAACTG
NFkB FW: CTACGGAACTGGGCAAATGT 145 Nagajyothi 
et al. (2012)RV: TCGAAATCCCCTCTGTTTTG
TNFa FW: CCGATGGGTTGTACCTTGTC 77 Cunningham 
et al. (2002)RV: GTGGGTGAGGAGCACGTAGT
18S FW: 
CTGCCCTATCAACTTTCGATGGTAG
100 Faroni, Smith, 
et al. (2014)
RV: CCGTTTCTCAGGCTCCCTCTC
MAG FW: CACCTTCTCGGAGCACAG 78 Faroni, Smith, 
et al. (2014)RV: GTTCCTGCCACCACTTCC
MBP FW: AGGACTCACACACGAGAACTACCC 121 Faroni, Smith, 
et al. (2014)RV: GGTGTTCGAGGTGTCACAATGTTC
PMP22 FW: CGGTTTTACATCACTGGATTCTTC 98 Faroni, Smith, 
et al. (2014)RV: TTGACATGCCACTCACTGT
P0 FW: TGACAACGGCACTTTCACA 118 Faroni, Smith, 
et al. (2014)RV: TCCCAACACCACCCCATA
BDNF FW: GGTATCCAAAGGCCAACTGA 183 Faroni, Smith, 
et al. (2014)RV: CTTATGAATCGCCAGCCAAT
T A B L E  1  Table of primers used in 
real time-PCR studies
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analysed with RotorGene-6000 series software (version 
1.7). The PCR conditions were set to: 1 step at 95°C for 
10 min to activate the HotStart DNA Taq Polymerase, fol-
lowed by 40 cycles of 15 s at 95°C, 30 s at 55°C and 30 s at 
72°C, where the fluorescence data were collected. The pro-
tocol was terminated with a melting curve program of 95°C 
for 1 min, 65°C for 2 min, and gradual change from 65°C to 
95°C, with a 1°C increase at each step. Data were analysed 
via the ΔΔCt method, and normalised for the housekeeping 
gene (18s) and the control groups (uninjured control and T0 
control nerves).
2.7 | Transmission electron microscopy
Following terminal anaesthesia and cervical spine dislo-
cation, mice were perfused transcardially with 2% para-
formaldehyde and 2% glutaraldehyde in sodium cacodilate 
buffer (0.1 M, pH 7.3) for fixation. The sciatic nerves were 
then harvested and immersed in the same fixative solu-
tion overnight at 4°C. Samples were postfixed in 2% OsO4 
(Sigma-Aldrich), washed in distilled water, stained with 
2% aqueous uranyl acetate, dehydrated in graded alcohol 
and embedded in Epon-Araldite resin. Ultrathin sections 
(ca. 70–80 nm) of the fixed sciatic nerves were collected 
on formvar coated single slot grids and counterstained with 
lead citrate, then examined with a Zeiss EM 10 electron 
microscope (Oberkochen, Germany). For morphological 
analysis, more than 25% of the total cross-sectional area 
of each nerve (corresponding to at least 25% of the total 
nerve cross-sectional area, about 90–100 fields) were ran-
domly selected using a systematic random-square sampling 
method throughout the entire nerve profile (Mayhew & 
Sharma, 1984) and Image Pro-Plus 6.0. The measurement 
of myelinated fibres (at least 1,500 fibres/animal), myelin 
thickness, G-ratio (ratio between inner axonal diameter and 
total outer diameter of the fibre) and irregular fibres [index 
of circularity (IC), calculated as squared fibre perimeter/4π 
fibre area, <0.75] were assessed. The number of Remak 
bundles, number of unmyelinated axons in each bundle, 
number of single unmyelinated and myelinated axons 
were counted. Data were expressed per unit of surface area 
(100 μm2) ± SEM.
2.8 | Statistical analysis
All statistical analyses were performed using GraphPad Prism 
(version 8.2.1 for Mac; GraphPad Software, San Diego, CA, 
USA). Statistical significance was evaluated by two-tailed 
unpaired t tests or two-way ANOVA. Results were consid-
ered significant at p < 0.05.
3 |  RESULTS
3.1 | Confirming PNS phenotype in Pfizer's 
P2X7R knockout mouse strain
Pfizer's P2X7 knockout (KO) mice (3-month-old males) 
were sourced from The Jackson Laboratory (B6.129P2-
P2rx7tm1Gab/J), and C57BL/6 wild type (WT) were used as 
controls. Firstly, we demonstrated the ablation of P2X7R 
by using specific primer sequences. Indeed, PCR analyses 
performed on tail biopsies or ear punches confirmed that 
the experimental mice express the KO sequence (280 bp), 
and not the WT sequence (363 bp). All control mice express 
the WT P2X7 sequence (363  bp), and heterozygote mice 
express both the WT and KO sequence (280 and 363  bp, 
Figure 1a).
Since significant differences have been reported in GSK 
and Pfizer's P2X7 KO mice (Sim et al., 2004), we proceeded 
to confirm the PNS phenotype we previously reported in 
GSK mice (Faroni, Smith, et al., 2014), in the newly acquired 
Pfizer model. Interestingly, we observed significant reduction 
of the protein levels of the main peripheral myelin proteins P0 
(****p < 0.0001), MBP (*p < 0.05) and MAG (**p < 0.01) 
using western blot analyses (Figure  1b). Moreover trans-
mission electron microscopy analyses confirmed the altered 
morphology of P2X7 KO mice, which feature a significantly 
higher number of Remak bundles (***p < 0.001), contain-
ing a higher number of unmyelinated axons (***p < 0.001, 
Figure 1c). Albeit not statistically significant, P2X7R knock-
out mice showed a reduced myelinated/unmyelinated axon 
ratio compared to WT controls, but the overall myelin thick-
ness was unaltered. Finally, the percentage of irregular fibres, 
with circularity index (IC) lower than 0.75, was significantly 
higher in P2X7R knockout mice compared to WT controls 
(*p < 0.05).
3.2 | Gene expression changes in DRG 
neurons following nerve transection
Given that peripheral nerve injury is accompanied with pro-
found changes in gene expression at the level of the DRG 
neurons (Martin et  al.,  2019), we investigated if some of 
these changes could be affected by the absence of P2X7R. 
We analysed the expression levels for markers of cell death, 
inflammation, survival and regeneration in DRG by real-time 
PCR, 1 week after peripheral nerve transection and no repair 
(Figure 2a). Peripheral nerve injury caused an increase in cas-
pase 2 (CASP2) gene expression level in DRG from both WT 
(ns) and P2X7 KO (**p < 0.01) mice, as well as an increase 
in caspase 3 (CASP3, ****p < 0.0001 WT; ***p < 0.001 
P2X7 KO) gene expression levels (Figure 2b).
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Markers of inflammation were also upregulated in DRG 
after nerve transection in both WT and P2X7R KO mice 
(Figure  2c). Indeed, nuclear factor kappa-light-chain-en-
hancer of activated B cells (NFkB) levels were marginally 
increased after injury in WT mice (ns), whereas in P2X7 
KO the increase was statistically significant (**p  <  0.01). 
Conversely, tumour necrosis alpha (TNFα) expression 
levels were significantly increased after injury in WT mice 
(*p < 0.05), but only marginally increased in P2X7 KO (ns).
Furthermore, we analysed markers of survival, nerve func-
tion and nociception such as Activating Transcription Factor 
3 (ATF3), Growth Associated Protein 43 (GAP43), Nerve 
Growth Factor (NGF) and galanin (GAL, Figure 2d). Nerve 
transection caused a significant increase in the expression 
F I G U R E  1  P2X7R knockout mice display different morphological characteristics compared to wild type controls. (a) Confirmation of 
ablation of the complete P2X7R sequence was performed by PCR using specific primers; KO mice only showed KO sequence of 280 bp, whereas 
in control mice only the WT amplicon (363 bp) was generated. Heterozygous mice showed both amplicons. (b) Western blot analysis of sciatic 
nerve homogenates taken from P2X7 KO mice showed that these animals express significantly less P0 (56 ± 4.96% versus WT, ****p < 0.0001), 
MBP (49.8 ± 10.2% versus WT, *p < 0.05), and MAG (47.2 ± 5.63% versus WT, **p < 0.01), when compared to the control WT animals. (c) 
Transmission electron microscopy (TEM) analysis of sciatic nerves revealed significant morphological differences between KO and control WT 
nerves. P2X7 KO nerves showed a higher number of Remak bundles compared to WT mice (0.617 ± 0.026 versus 0.345 0.022 per 100 μm2, 
***p < 0.001). The Remak bundles also contained a significantly higher number of unmyelinated axons (8.314 ± 0.428 versus 4.424 ± 0.309 
per 100 μm2, ***p < 0.001). The ratio between myelinated and unmyelinated axons was lower in KO compared to WT controls, although this 
was not statistically significant (0.493 ± 0.041 KO versus 0.673 ± 0.140 WT, ns). We found no significant differences in myelin thickness 
(1.118 ± 0.019 μm WT versus 1.156 ± 0.008 μm KO, ns). The percentage of irregular fibres with circularity index (IC) lower than 0.75 was 
significantly higher in the KO nerves compared to WT (52 ± 3.907% versus 28 ± 5.925%, *p < 0.05)
F I G U R E  2  Gene expression changes in DRG following peripheral nerve transection and no repair. (a) Sciatic nerves from WT and P2X7 KO 
mice were transected with no attempted repair and DRG were harvested 1 week following the injury to analyse gene expression changes (n = 5). 
(b) CASP2 was upregulated in DRG after the peripheral injury compared to DRG from uninjured mice (WT: 1.270 ± 0.137 fold change versus 
1.000 ± 0.13, ns; KO: 1.460 ± 0.082 fold change versus 0.836 ± 0.057, **p < 0.01). CASP3 was also upregulated in DRG after injury (WT: 
3.928 ± 0.357 fold change versus 1.000 ± 0.142, ****p < 0.0001; KO: 3.360 ± 0.552 fold change versus 0.548 ± 0.045, ***p < 0.001). (c) The 
increase in NFkB expression after injury was only marginal in DRG from WT mice (1.440 ± 0.162 fold change versus 1.000 ± 0.098, ns), whereas 
it was statistically significant in P2X7 KO mice (1.686 ± 0.161 fold change versus 0.888 ± 0.053, **p < 0.01). TNFα expression was increased 
in DRG from injured groups in both WT (4.652 ± 1.501 fold change versus 1.367 ± 0.396, *p < 0.05) and P2X7 KO mice strain (2.854 ± 0.589 
fold change versus 0.987 ± 0.210, ns). (d) ATF3 was significantly upregulated in injured DRGs from both groups (WT: 107.540 ± 15.412 fold 
change versus 1.000 ± 0.176, ****p < 0.0001; KO: 72.886 ± 10.243 fold change versus 0.616 ± 0.143, ***p < 0.001). GAP43 also followed 
a similar trend (WT: 4.916 ± 0.785 fold change versus 1.000 ± 0.224, **p < 0.01; KO: 5.836 ± 0.937 fold change versus 0.984 ± 0.107, 
***p < 0.001). Similarly, NGF expression was upregulated in both WT (3.152 ± 0.535 fold change versus 1.000 ± 0.286, **p < 0.01) and P2X7 
KO (1.984 ± 0.361 fold change versus 0.532 ± 0.090, *p < 0.05) DRGs from the injured groups. Finally, DRGs from injured WT mice expressed 
significantly more GAL compared to uninjured controls (28.000 ± 4.288 fold change versus 1.000 ± 0.091, ****p < 0.0001), similarly to P2X7 
KO mice (47.570 ± 3.515 fold change versus 1.004 ± 0.116, ****p < 0.0001). Interestingly, GAL expression levels were significantly higher in 
injured P2X7 KO compared to injured WT DRGs (***p < 0.001)
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levels of ATF3 in the DRGs of both WT (****p < 0.0001) 
and P2X7 KO mice (***p  <  0.001). Similarly, levels of 
GAP43 were significantly increased in WT (**p < 0.01) and 
P2X7 KO (***p < 0.001) DRGs after injury. NGF was also 
upregulated in DRG after injury in both WT (**p < 0.01) 
and KO (*p  <  0.05) groups. Overall, no major differences 
in the expression levels were observed between the WT and 
KO mice. Nevertheless, we found increased expression levels 
of the neuropeptide GAL in both WT (****p < 0.0001) and 
P2X7 KO DRGs (****p < 0.0001) after injury, and GAL ex-
pression levels were significantly higher in injured P2X7 KO 
DRGs compared to injured WT (***p < 0.001).
3.3 | Degeneration and regeneration 
speed are not affected by P2X7R absence
To assess the effect of P2X7R ablation on the efficacy of 
nerve regrowth we performed a sciatic nerve transection 
with immediate repair, and performed histological analyses 
on longitudinal nerve sections 1 and 2 weeks after survival 
(Figure 3a). One week after the injury and repair, evidence 
of growing axonal cones could be observed (neurofilament 
200 staining, NF200, green) at the injury/repair site (red 
line); whereas in the distal stump the distribution of the ax-
onal debris suggested ongoing Wallerian degeneration, with-
out major differences between the WT and P2X7 KO groups 
(Figure  3b). Following 2  weeks survival, NF200 staining 
(green) showed complete regeneration of newly formed 
axons within the distal stump in both experimental groups 
(Figure 3c).
To confirm that WD is not affected by the absence of 
P2X7R, we performed gene expression analyses in an ex 
vivo model of WD. We chose an ex vivo, rather than in vivo 
model in order to minimise the systemic effects of P2X7R 
ablation, and focus on the effects of P2X7R removal mainly 
in Schwann cells. Sciatic nerves were collected from WT and 
P2X7 KO mice, and cultured as explants for 72 hr to recapit-
ulate WD in vitro.
F I G U R E  3  Speed of degeneration and regeneration is unaltered 
in P2X7 KO mice. (a) Sciatic nerves were cut and immediately 
repaired in both experimental groups (n = 5) and regeneration was 
assessed after 1 and 2 weeks. (b) Immunohistostaining of NF200 
(green) following 1 week survival highlighted axonal growth at the 
injury site (red line) and degenerating axons in the distal stump. We 
observed no differences in the histological features of the degenerating 
nerves between the experimental (right) and the control (left) groups. 
(c) Similarly, 2 weeks after the repair the axons had regenerated 
throughout the distal stump, and no differences in regeneration speed 
was observed between the control (WT, left) and experimental groups 
(P2X7 KO, right)
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We started by analysing the levels of the main myelin 
proteins in the peripheral nerves: MAG, MBP, PMP22 and 
P0. Freshly isolated sciatic nerves (T0) from P2X7 KO mice 
expressed significantly higher levels of MAG (**p < 0.01, 
Figure  4a). Following 72  hr of in vitro WD (T72), MAG 
expression levels were significantly decreased in both WT 
and P2X7 KO nerves (****p  <  0.0001, Figure  4a). Basal 
MBP gene expression levels were similar in WT and P2X7 
KO (ns, Figure 4b), and following 72 hr of degeneration in 
vitro MBP expression was significantly decreased in both 
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(***p < 0.001 for WT, and ****p < 0.0001 for P2X7 KO 
respectively Figure 4b). At T0, P2X7 KO nerves expressed 
significantly higher levels of PMP22 compared to WT con-
trols (***p < 0.001, Figure 4c); at T72, PMP22 gene expres-
sion levels were significantly decreased (****p  <  0.0001, 
Figure  4c). P0 expression levels were marginally higher at 
T0 in P2X7 KO compared to WT (ns, Figure  4d), and at 
T72 there was a significant decrease of expression levels 
in both WT (**p < 0.01) and KO (****p < 0.0001) nerves 
(Figure 4d).
We then analysed expression levels of neurotrophic fac-
tors involved in WD such as nerve growth factor (NGF) 
and brain derived neurotrophic factor (BDNF). BDNF ex-
pression levels were marginally higher in P2X7 KO com-
pare to WT, although this was not statistically significant 
(ns, Figure  4e). In both experimental groups, BDNF lev-
els were greatly upregulated after ex vivo degeneration 
(****p  <  0.0001, Figure  4e). No significant differences 
were observed in BDNF expression between P2X7R KO and 
WT at T72. Similarly, NGF levels were higher in P2X7 KO 
nerves compare to WT (ns, Figure 4f), and the expression of 
NGF was significantly increased in both groups after WD 
(****p < 0.0001), with no significant differences between 
the two (ns, Figure 4f).
Finally, we analysed gene expression changes of apop-
totic genes such as Caspase-2 (CASP2) and Capsase-3 
(CASP3). CASP2 levels were similar in P2X7 KO nerves 
compared to WT at both T0 and T72 (ns), with only a mar-
ginal but not significant increase between the two time 
points within each group (ns, Figure  4g). CASP3 expres-
sion was marginally lower in P2X7 KO compared to WT 
nerves at T0 (ns), and significantly increased in both groups 
(****p < 0.0001), without significant differences between 
WT and KO (Figure 4h).
3.4 | Re-myelination following nerve 
regeneration is delayed in P2X7 KO mice
To assess if the absence of P2X7R affects the capability of 
Schwann cells to remyelinate regenerating axons, we per-
formed morphometric analyses of the distal stumps of re-
generated nerves from WT and KO 4 and 8 weeks after the 
injury. The light and transmission electron microscopy anal-
yses showed a different regenerating phenotype in peripheral 
nerves from injured P2X7R KO mice compared to control 
animals (WT). At 4 weeks after the injury, the P2X7R nerves 
had a significantly lower number of Remak bundles com-
pared to WT (***p < 0.001, Figure 5a). By week 8, the num-
ber of Remak bundles in the P2X7 KO nerves had increased 
significantly (***p  <  0.001) compared to 4  weeks P2X7R 
nerves, and was similar to WT nerves (ns). At 4 weeks, the 
Remak bundles in the injured KO nerves contained a sig-
nificantly lower number of unmyelinated axons compared to 
WT (***p < 0.001, Figure 5b), and this did not change at 
the 8 weeks time point (ns), where the unmyelinated axons 
within the KO Remak were still lower compared to 8 weeks 
WT controls (***p < 0.001, Figure 5b). The effect at 4 weeks 
was also confirmed in transmission electron microscopy im-
ages (Figure 6a), in which the unmyelinated axons appeared 
lower in KO nerves compared to WT. At 4 weeks after injury 
we also found a higher number of single unmyelinated axons 
(not contained within a Remak bundle) in P2X7 KO nerves 
compared to WT (***p < 0.001, Figure 5c). The number of 
single unmyelinated axons significantly increased in P2X7 
KO nerves after further 4 weeks (***p < 0.001), although at 
8 weeks the number of single unmyelinated axons was signifi-
cantly higher in WT nerves compared to P2X7 KO (*p < 0.05, 
Figure 5c). This was further shown in transmission electron 
microscopy images (Figure 6b) still confirming a decrease in 
F I G U R E  4  Wallerian degeneration is similar in WT and P2X7 KO mice. (a) Gene expression analyses showed that basal MAG levels 
(T0) were higher in P2X7 KO nerves compared to controls (2.474 ± 0.546 fold increase versus 1.051 ± 0.119, **p < 0.01). Nerves were left to 
degenerate for 72 hr (T72) in vitro to recapitulate Wallerian degeneration (WD) and MAG expression levels were significantly decreased in both 
experimental groups (0.068 ± 0.010 and 0.059 ± 0.006 for WT and P2X7R KO respectively, ****p < 0.0001). (b) MBP levels were similar at 
T0 between WT and KO groups (1.073 ± 0.147 versus 1.324 ± 0.280, ns), and significantly decreased following 72 hr: 0.112 ± 0.010 in WT 
(***p < 0.001); and 0.092 ± 0.007 in P2X7 KO nerves (****p < 0.0001). (c) PMP22 levels were significantly higher in P2X7 KO at T0 versus 
WT (3.765 ± 0.758 fold change versus 1.311 ± 0.265, ***p < 0.001), and greatly decreased after 72 hr of degeneration in vitro (0.121 ± 0.014 WT, 
and 0.085 ± 0.005 P2X7 KO, ****p < 0.0001). (d) P2X7R KO nerves expressed slightly higher levels of P0 compared to WT (2.025 ± 0.438 fold 
change versus 1.355 ± 0.253, ns), and after 72 hr P0 levels were significantly decreased in both WT (0.035 ± 0.003, **p < 0.01) and P2X7 KO 
(0.030 ± 0.002, ****p < 0.0001). (e) P2X7 KO nerves showed higher levels of BDNF (15.745 ± 5.770) compared to WT nerves (1.114 ± 0.191), 
although this was not statistically significant (ns). Following degeneration, BDNF levels significantly increased in both WT (277.367 ± 18.096) 
and P2X7 KO nerves (315.461 ± 18.815, ****p < 0.0001). (f) NGF expression was higher in KO nerves compared to WT (30.757 ± 11.008 
fold change versus 6.585 ± 3.539, ns), and it significantly increased in both WT (712 ± 115.285, ****p < 0.0001) and P2X7 KO (769 ± 42.678, 
****p < 0.0001) nerves. (g) WT and KO nerves expressed similar levels of CASP2 (1.101 ± 0.153 versus 1.553 ± 0.251, respectively); expression 
levels did not significantly change following ex vivo WD (1.744 ± 0.153 and 1.824 ± 0.089 for WT and P2X7 KO respectively, ns). (h) P2X7 KO 
nerves expresses lower levels of CASP3 (0.624 ± 0.074) compared to WT (1.050 ± 0.155), although this was not statistically significant. CASP3 
was significantly upregulated in both groups at T72 (3.123 ± 0.165 and 3.458 ± 0.191 for WT and P2X7 KO, respectively, ****p < 0.0001)
   | 11MAGNAGHI et Al.
single unmyelinated fibres. Despite these changes, the total 
number of unmyelinated axons (both in Remaks and singles) 
was lower in P2X7 KO nerves compared to WT at both time 
points (***p < 0.001), while a weak but significant increase 
was observed in P2X7 KO between 4 and 8 weeks after in-
jury (***p < 0.001, Figure 5d). Interestingly, transmission 
electron microscopy images showed a particular structure 
formed by a Schwann cell, enveloping some unmyelinated 
axons, and surrounding a myelinated fibre (Figure  6c). At 
4  weeks after the injury the ratio between myelinated and 
unmyelinated axons was significantly higher in P2X7 KO 
mice compared to WT, (***p < 0.001, Figure 5e); this ratio 
significantly increased (***p < 0.001) at the 8 weeks time 
point (Figure 5e). The overall number of myelinated axons 
was significantly lower in P2X7 KO nerves compared to WT, 
at both time points considered (***p < 0.001, Figure 5f), al-
though it significantly increased in P2X7 KO between 4 and 
8 weeks after the injury (***p < 0.001, Figure 5f). Myelin 
thickness was significantly lower in P2X7 KO nerves com-
pared to WT at 4 weeks (***p < 0.001, Figure 5g), and rose 
significantly in P2X7 KO at 8 weeks, when compared to WT 
(***p  <  0.001, Figure  5g). Interestingly, myelin thickness 
augmented significantly in P2X7 KO nerves comparing the 4 
to the 8 weeks time point (***p < 0.001, Figure 5g; see also 
Figure 6a,b). Conversely, in P2X7 KO nerves the G-ratio was 
higher than WT at 4 weeks after injury and lower than WT 
after 8 weeks, with a significant decrease between the 2 time 
points (***p < 0.001, Figure 5h). Finally, an increase in the 
percentage of irregular fibres (IC lower than 0.75) was found 
in P2X7 KO nerves at 4 weeks (65% in KO versus 47% in 
F I G U R E  5  Remyelination following injury is affected by the absence of P2X7 receptors. (a) The number of Remak bundles was lower 
in the distal stump of regenerating P2X7 KO nerves 4 weeks after the injury, when compared to WT (0.8595 ± 0.030 versus 1.261 ± 0.044 Rb 
per 100 μm2, ***p < 0.001). After 8 weeks, the Remak bundles in P2X7 KO nerves were increased when compared to 4 weeks (***p < 0.001), 
however there was no significant difference between KO and WT nerves (1.404 ± 0.087 and 1.504 ± 0.060 Rb per 100 μm2, respectively). 
(b) The number of unmyelinated axons contained within the Remak bundles was lower in P2X7 KO compared to WT, respectively at 4 weeks 
(3.246 ± 0.13 versus 5.189 ± 0.23 axons per 100 μm2, ***p < 0.001) and 8 weeks (3.614 ± 0.17 versus 5.202 ± 0.25 axons per 100 μm2, 
***p < 0.001) after the injury. (c) Single unmyelinated axons, not contained in Remak bundles were found in higher numbers in P2X7 KO nerves 
at 4 weeks after the injury, when compared to WT (0.5976 ± 0.027 versus 0.4058 ± 0.025 axons per 100 μm2, ***p < 0.001). At 8 weeks the 
number of single unmyelinated axons was significantly higher (*p < 0.05) in WT nerves compared to P2X7 KO (1.271 ± 0.048 and 1.087 ± 0.052 
for WT and P2X7 KO respectively). (d) The overall number of unmyelinated axons (in Remak bundles plus single axons) was lower in P2X7 
KO nerves compared to WT, respectively at 4 weeks (3.246 ± 0.13 versus 5.189 ± 0.23, ***p < 0.001), and 8 weeks (3.614 ± 0.17 versus 
5.202 ± 0.25, ***p < 0.001) after injury. However, in P2X7 KO was found a weak but significant increase between 4 and 8 weeks after injury 
(***p < 0.001). (e) At 4 weeks after regeneration, the ratio between myelinated and unmyelinated fibres was higher in P2X7 KO mice versus WT 
(0.1098 ± 0.0073 versus 0.06049 ± 0.0047, ***p < 0.001). This ratio significantly increased (***p < 0.001) in P2X7 at the 8 week time point 
when compared at 4 weeks, whereas at 8 weeks here was no difference between WT and KO (0.1633 ± 0.021 and 0.1731 ± 0.011, respectively, 
***p < 0.001). (f) The number of myelinated axons was lower in P2X7 KO compared to WT at 4 weeks (1.611 ± 0.040 versus 1.793 ± 0.062, 
***p < 0.001) and 8 weeks (2.906 ± 0.071 versus 3.324 ± 0.054, ***p < 0.001), albeit the number of myelinated axons significantly increased 
(***p < 0.001) in KO nerves at 8 weeks when compared to 4 weeks post injury. (g) Myelin thickness was lower in P2X7 KO nerves compared 
to WT at 4 weeks after injury (0.5856 ± 0.0051 versus 0.6227 ± 0.0059, ***p < 0.001), however after further 4 weeks P2X7 KO nerves 
showed thicker myelin versus WT (0.7700 ± 0.0059 versus 0.7188 ± 0.0044, ***p < 0.001). In P2X7 KO, the myelin thickness augmented 
significantly (***p < 0.001), comparing the 4 to the 8 week time point. (h) The G-ratio was higher in P2X7 KO nerves compared to WT at 
4 weeks (0.6396 ± 0.0020 versus 0.6016 ± 0.0022, ***p < 0.001), whereas it was lower in KO compared to WT at 8 weeks (0.5807 ± 0.0018 
versus 0.6010 ± 0.0015, ***p < 0.001). Moreover, the G-ratio in P2X7 KO nerves significantly decreased between the 2 time points considered 
(***p < 0.001)
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WT), although this difference flattened at 8 weeks (P2X7 KO 
nerves 76% versus WT 79%).
4 |  DISCUSSION
Pharmaceutical therapies for peripheral nerve injury are cur-
rently unavailable. A large number of pharmaceutical targets 
have been proposed as promising candidates for the devel-
opment of novel therapies for peripheral nerve regenera-
tion. In particular, extensive research has been focusing on 
neurotransmitters such as GABA, ATP and Ach, and their 
receptors, as systems to be targeted. In previous work, we 
have shown how GABA receptors play important roles in 
determining the fate of Schwann cells during development 
(Faroni & Magnaghi, 2011; Magnaghi et al., 2009). Indeed, 
mice lacking GABA-B1 receptors in the whole organism 
(Magnaghi et  al.,  2008), or selectively in Schwann cells 
(Faroni, Castelnovo, et  al.,  2014), showed an altered phe-
notype of peripheral nerve morphology and phenotype, 
highlighting the importance of GABA-B1 receptors for the 
SC commitment to a non-myelinating phenotype. This was 
also confirmed with in vitro cultures of SC and DRG neu-
rons from GABA-B1 knockout animals (Faroni et al., 2019). 
Treatment with GABA ligands modulates the production and 
release of neurotrophins in SC in vitro (Faroni, Calabrese, 
et  al.,  2013), and promotes nerve regeneration in a sciatic 
nerve lesion model in vivo (Magnaghi et  al.,  2014). Ach 
signaling has also been extensively associated with the reg-
ulation of myelination, and particularly more recently with 
the regulation of Schwann cell physiology during develop-
ment and remyelination following injury (Fields et al., 2017). 
Indeed, Schwann cells express several muscarinic receptors, 
with M2 being specifically important for Schwann cell pro-
liferation and myelin formation (Loreti et  al.,  2006, 2007; 
Uggenti et al., 2014). Similarly, purinergic receptors for ATP 
have been identified in several glial cells, including Schwann 
cells, where they take part in several neuron-glia interac-
tions that are fundamental for glial cell pathophysiology 
(Fields & Burnstock, 2006; Fields & Stevens, 2000; Lecca 
et al., 2012; Verkhratsky et al., 2009). Indeed, Schwann cells 
located along axon segments respond to ATP and other neu-
rotransmitters released by axons during electrical stimula-
tion, which in turn may affect Schwann cell proliferation, 
differentiation, and myelination (Fields & Burnstock, 2006; 
Fields et al., 2017; Fields & Stevens, 2000; Fields & Stevens-
Graham, 2002; Stevens & Fields, 2000; Stevens et al., 1998, 
2002). Furthermore, several cellular mechanisms for ATP 
release, including P2X7R, have been identified in non-neu-
ronal cells (Fields, 2011).
In a previous study, we demonstrated that P2X7 recep-
tors localise mainly in myelinating Schwann cells in the PNS. 
Moreover we showed that peripheral nerves from P2X7 KO 
mice possess an altered molecular and morphological pheno-
type, suggesting a key role for P2X7R to determine Schwann 
cell fate during development (Faroni, Smith, et  al.,  2014). 
This peculiar phenotype results was described in the P2X7 
KO mice developed by GSK, (Chessell et  al.,  2005); how-
ever, Pfizer developed a similar knockout model (Solle 
et  al.,  2001), which showed similar but not identical char-
acteristics (Sim et al., 2004). For this reason, in the current 
work we repeated some of the initial characterisation of 
the peripheral nerves phenotype studied in GSK P2X7 KO 
(Faroni, Smith, et al., 2014), also in the Pfizer mice devel-
oped by Solle et al. (Solle et al., 2001). As in the GSK P2X7 
KO model (Faroni, Smith, et  al.,  2014), Pfizer P2X7 KO 
mice also showed reduced expression of myelin proteins P0, 
MBP and MAG, as well as featuring the main morphometric 
properties of the GSK model (increased number of Remak 
and unmyelinated axons, as well as irregular fibres).
F I G U R E  6  Electron microscopy images from WT and P2X7 
KO cross-sectioned nerves following injury and repair. Comparison 
between nerve cross-sections of WT and P2X7 KO mice at 4 (a) and 8 
(b) weeks post injury showing thicker myelinated fibers in P2X7 KO 
mice at 8 weeks (white arrowheads), and a lower number of single 
unmyelinated axons (white arrows) compared to WT. (c) Electron 
micrograph from a cross-section of P2X7 sciatic nerve 4 weeks post 
injury, showing a Schwann cell enveloping some unmyelinated axons 
that surrounds a myelinated fiber. Scale bars 5μm
   | 13MAGNAGHI et Al.
Furthermore, in this study, we focused on the role or 
P2X7 receptor during injury and repair. Using ex vivo and in 
vivo models of nerve regeneration, we found that the absence 
of P2X7R does not affect the degenerative phase (Wallerian 
degeneration) that follows nerve injury and does not influ-
ence the speed of axonal regeneration. Nevertheless, EM 
studies showed that re-myelination is delayed in P2X7 KO 
mice, suggesting a role for P2X7R in the determination of 
the myelinating phenotype in injury and repair, in the same 
way it does during development. Indeed, KO mice showed a 
lower number of myelinated axons compared to WT at both 
4 weeks and 8 weeks after the injury and repair. The number 
of Remak bundles was also lower in KO nerves 4 weeks after 
injury, although there was no difference in number of Remak 
after 8 weeks between WT and P2X7 KO. Additionally, the 
Remak bundles in regenerating KO nerves contained a lower 
number of unmyelinated axons at both 4 and 8 weeks after 
injury. Interestingly, at 4 weeks during regeneration we found 
an increased number of single unmyelinated axons (not be-
longing to Remak) in KO nerves compared to WT, with an 
inverted trend at 8 weeks. We believe that the increased num-
ber of single unmyelinated axons at 4 weeks is a feature of 
delayed re-myelination. Indeed, these axons could have been 
sorted for myelination, but yet to be myelinated. At 8 weeks 
following the repair the situation is inverted with a higher 
number of single unmyelinated axons in the WT compared to 
the controls. We can speculate that beside being delayed, my-
elination is also generally hindered in the absence of P2X7R. 
Indeed, this would explain the higher number of unmyelin-
ated single axons in WT at 8 weeks, with a re-myelination 
program that is still active in WT mice, but delayed in P2X7 
KO. The slower re-myelination profile in the KO mice is 
also further confirmed by the reduced number of myelinated 
axons at both 4 and 8 weeks, compared to WT. Overall, the ra-
dial sorting is a developmental physiologic process in which 
the Schwann cells choose mostly larger axons to myelinate. 
Radial sorting defects may occur in neuropathologic compli-
cations of the PNS. Interestingly, our observations corrobo-
rate the evidence that P2X7R might have a role in regulating 
the radial sorting process (Feltri et al., 2016), as shown by 
the presence of structures composed of unmyelinated axons 
surrounding a myelinated fibre (electron micrographs), typ-
ical sign of morphological defects in radial sorting (Feltri 
et al., 2016).
Furthermore, myelin thickness is lower in KO at 4 weeks; 
this is because the higher number of single unmyelinated 
(or lightly myelinated) axons causes the overall thinning of 
myelin thickness. This is further confirmation that myelin-
ation is delayed, together with the lower number of myelin-
ated axons at both time points. Myelin thickness is higher in 
P2X7 KO nerves at 8 weeks. Similarly to what stated before, 
myelination is not only delayed in KO, but might also last 
less in general. Indeed, if this was the case the more active 
myelination program in WT would cause the overall myelin 
thickness to be lower at 8 weeks (due to an increased number 
of single unmyelinated/lightly myelinated axons still actively 
myelinating). Altogether, these complicated findings point 
towards the conclusion that re-myelination is delayed and 
globally hindered in the absence of P2X7 receptors.
In the acute phase following peripheral nerve injury, ex-
pression of P2X7R is upregulated in Schwann cells, which 
is associated with Schwann cell proliferation mediated by 
ATP (Song et al., 2015). With respect to demyelinating neu-
ropathies, Schwann cells taken from a rat model of Charcot-
Marie-Tooth 1A show abnormally high intracellular Ca2+ 
concentration due to overexpression of P2X7R mediated by 
peripheral myelin protein 22 (PMP22). In this animal model, 
the P2X7R reversible antagonist A438079 improved my-
elination in both in vitro organic DRG cultures, and in vivo 
histologic analysis. Consequentially these animals showed 
significant improvements in muscle strength and distal motor 
latencies compared to placebo controls, however, com-
pound muscle action potentials remained unaltered (Sociali 
et  al., 2016). Studies in rat Schwann cells have shown that 
exposure to high concentrations of ATP or P2X7R agonists 
(BzATP) induce significant rapid cell death, increasing mem-
brane permeability to large molecules including ethidium. 
Furthermore, these responses were not seen with irreversible 
(oxaTP) or reversible (A438079) antagonists, or in P2X7R 
KO mice, therefore suggesting that P2X7R is responsible for 
ATP-induced Schwann cell death in vitro (Faroni, Rothwell, 
et al., 2013; Luo et al., 2013). Considering that ATP is pres-
ent in high concentrations at the injury site, P2X7R is likely 
to be a mediator of Schwann cell death following injury.
Following nerve transection, structural proteins such as 
P0, PMP22, MAG and MBP are all rapidly downregulated 
(Mirsky & Jessen, 1999). On the contrary, neurotrophic fac-
tors such as NGF and BDNF are all upregulated, enabling 
axonal elongation and neuronal survival (Chen et al., 2007). 
Neurotrophins, such as NGF and BDNF, are fundamental in 
the guidance of axonal elongation following peripheral nerve 
injury (Jessen & Mirsky, 2016). Interestingly, at T0 the P2X7 
KO had a higher expression of all myelin proteins (i.e. P0, 
PMP22, MBP, MAG) compared to WT, corroborating the 
hypothesis of a strong correlation between the P2X7R and 
myelin proteins, and its involvement in nerve myelination 
(Faroni, Smith, et  al.,  2014; Nobbio et  al.,  2009). In this 
study, following 72 hr of in vitro degeneration, we success-
fully recapitulated several aspects of in vivo WD, including 
the downregulation of myelin proteins and the upregulation 
of neurotrophic growth factors (Faroni et al., 2015). Moreover 
72 hr of in vitro WD also increased cell death, according to in 
vivo (Faroni et al., 2015). Indeed, expression of both caspase 
2 and caspase 3, which function as central regulators of cell 
death (D'Amelio et al., 2010), increased after injury and ex 
vivo degeneration, suggesting that cell death is occurring.
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Caspase 3 showed a higher degree of upregulation in gene 
expression levels compared to caspase 2 in both WT and P2X7 
KO nerves. Hanley et al. suggested that caspase 3 activation is 
ATP-concentration dependent and thus may be downstream 
of the P2X7R (Hanley et al., 2012). Nevertheless, caspase 3 
mediated cell death is independent of other apoptosis path-
ways, such as caspase-1 (Hanley et al., 2012), and therefore 
other cell death mechanisms might be occurring. The activa-
tion of both caspase-3 and P2X7R is known to lead to mem-
brane blebbing and subsequent cell death, via the degradation 
of cytoskeleton proteins (Janicke et al., 1998). Importantly, 
some of these changes also reflected on the DRGs, in which 
inflammatory mediators (e.g. NFkB, TNFα, etc.) increased 
following nerve transection, both in WT and P2X7 KO. Gene 
expression changes in DRGs following peripheral nerve tran-
section are part of the pathophysiological response of the 
PNS to nerve injury (Martin et al., 2019). As NFκB is ubiq-
uitously expressed, the increase observed in the P2X7 KO 
may highlight an increased recruitment of inflammatory cells 
to the DRG, compared to the WT. Inflammation is required 
to clear the cellular debris and improve the environment for 
regeneration, however, it also increases cellular death and can 
counterbalance the recovery (Rock, 2009). Indeed, TNF is an 
apoptotic mediator, associated with a variety of other roles, 
including necrosis (Bradley, 2008), and DRG excitability de-
termining neuropathic pain (Zhang et al., 2007). The TNFα 
pro-apoptotic effect was also associated to upregulation of 
caspase-2 and caspase-3, implying that an increase in cell 
death also occurred.
Nevertheless, in the DRGs we also found upregulation 
of factors that oppose the increase of cell death mediators, 
such as the transcription factor ATF3 or the neuropeptide gal-
anin which are reported to improve neuronal survival after 
injury (Hobson et al., 2008; Holmberg et al., 2005). ATF3 is 
generally considered a marker of nerve injury, indeed naïve 
animals have a very low expression of ATF3 in the DRG neu-
rons, while an injury induces its high upregulation (Tsujino 
et al., 2000). Given that ATF3 has a role in controlling the 
F I G U R E  7  The role of P2X7 receptor on peripheral nerve development and regeneration (a) During development, Schwan cells, deriving 
from the neural crest, can differentiate towards a myelinating or non-myelinating phenotype. P2X7 receptors play a role in the determination of 
SC fate; indeed, mice lacking P2X7R possess higher number of unmyelinated fibres in the peripheral nerves, with a lower number of myelinated 
axons, suggesting that P2X7 receptors are essential for the transition of Schwann cells from immature to a myelinating phenotype (Faroni, Smith, 
et al., 2014). (b) Following injury and during Wallerian degeneration, both myelinating and non-myelinating Schwann cells loose contact with 
the axons and de-differentiate into a “repair” phenotype which drives nerve regeneration (Jessen & Mirsky, 2016). After the nerve is regenerated 
the repair Schwann cells re-differentiate into myelinating or non-myelinating Schwann. Herein, we showed that the absence of P2X7R does not 
affect the Wallerian degeneration phase following nerve injury. Furthermore, speed of nerve regrowth is unaltered in P2X7 KO mice, compared to 
controls. Nevertheless, lack of P2X7 receptors hinders the re-myelinating potential of repair Schwann cells resulting in delayed and less effective 
remyelination
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expression of other genes that are important for recovery, it 
is one of the earliest genes to be upregulated following an 
injury (Hyatt Sachs et al., 2007). Moreover, galanin upreg-
ulation after injury is also in accordance to data on injured 
superior cervical ganglia (Schreiber et al., 1994). It is known 
that galanin is predominantly located in the small/medium 
neurons within the DRG, whereas P2X7R is mainly found in 
the surrounding glial cells, which suggests important func-
tions for neuron-glia communication (Zhang et  al.,  2007). 
Hence, in order to unveil the signalling cascade triggering 
the galanin gene expression increase, we hypothesised that 
the altered gene expression of galanin may be a result of the 
loss of this communication mechanism. Finally, we found 
that growth factors were upregulated in DRGs after injury, 
likely in order to promote axonal elongation. Indeed, it is 
well established that NGF is upregulated after injury in DRG 
(Lindsay, 1988; McMahon, 1996; Woolf & Costigan, 1999), 
and is vital for recovery of the DRG neurons (Lindsay, 1988). 
However, NGF exerts important roles in the neuroregener-
ative process as well as in the neuroinflammatory response 
within the adult DRG sensory neurons (McMahon,  1996; 
Woolf & Costigan,  1999). The drop in NGF expression 
has also been correlated with the increase in galanin (Rao 
et al., 1993; Shadiack et al., 1998).
Collectively, our findings point to the role of P2X7R 
in the determination of Schwann cell fate, facilitating the 
transition of Schwann cells from immature to a myelinat-
ing phenotype (Figure 7; Lindsay, 1988; McMahon, 1996; 
Woolf & Costigan, 1999). Namely, these receptors support 
the regeneration and re-myelination following peripheral 
nerve injury and in demyelinating neuropathies. More work 
needs to be done to understand the the role of P2X7R in 
non-myelinating Schwann cells, and to exploit P2X7 recep-
tors as potential pharmacological targets for novel nerve re-
pair strategies.
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